Kornimate/medical-research-clean huggingface dataset:
survey of guideline adherence for treatment of systolic heart failure in real world

Conditions: Heart Failure, Congestive

Summary: the purpose of this study is to survey the guideline compliance of the cardiologists in the treatment of systolic heart failure in korea

major improvement in the medical management of chf has been achieved in the past decades. but there is no doubt that prognosis of heart failure patients remains poor. the compliance to the standard treatment can be one of reasons. but very little data concerning this in korea is available.

Eligibility criteria:
inclusion criteria: * subjects admitted to hospital with systolic heart failure(lvef under 45%) in 2009 * subjects, age 20 or/and above * subjects admitted to hospital (emergency area, to internal medicine or to cardiology wards, ccu or intensive care) with dyspnea and verification of heart failure based on following criteria; * symptoms typical of heart failure : breathlessness at rest or on exercise, fatigue, tiredness, ankle swelling and signs typical of heart failure : tachycardia, tachypnoea, pulmonary rales, pleural effusion, raised jugular venous pressure, peripheral oedema, hepatomegaly * objective evidence of a structural or functional abnormality of the heart at rest : cardiomegaly, third heard sound, cardiac murmurs, abnormality on the echocardiogram, raised natriuretic peptide concentration exclusion criteria: * subject who expired during hospitalization

Keywords: guideline adherence systolic heart failure
translation and validation of the french mpcosq (mpcosq-f).

Conditions: Polycystic Ovary Syndrome Health-related Quality of Life

Summary: this study is a prospective, observational, bicentric study, evaluating the validity and reliability of a french version of the mpcosq questionnaire (mpcosq-f), used to assess health-related quality of life (hrqol) in women with polycystic ovary syndrome. the first stage of the study consisted in translating the questionnaire from english to french. patients agreeing to take part in the study will complete the mpcosq-f and the sf-36 (generic hrqol questionnaire). after 1 to 2 weeks, patients will receive the mpcosq-f and complete it again.

the aim of this study is to assess the validity and reliability of a french version of the mpcosq questionnaire (mpcosq-f), used to assess health-related quality of life (hrqol) in women with polycystic ovary syndrome. women aged 18 to 45 years with a diagnosis of polycystic ovary syndrome will be included. the first stage of the study consisted in translating the questionnaire from english to french. patients agreeing to take part in the study will complete the mpcosq-f and the sf-36 (generic hrqol questionnaire). after 1 to 2 weeks, patients will receive the mpcosq-f and complete it again. the pre-test phase purpose is to appraise the face validity and feasibility of the questionnaire through phone interviews with the thirty first respondents. in the final phase, we aimed to evaluate the validity and reliability of the mpcosq, and to compare it to the sf-36.

Eligibility criteria:
inclusion criteria: * women aged 18 to 45 * fluent in french * having a diagnosis of pcos according to the international recommendations published in 2023 * willing to participate in the study * affiliated to the french social security system exclusion criteria: * diagnosis of adrenal hyperplasia, androgen-producing tumor, cushing's syndrome, or thyroid disorder * pregnancy or breast-feeding * under legal protection

Keywords: polycystic ovary syndrome pcos quality of life health-related quality of life mpcosq questionnaire sf-36 french
michl-trial: impact of peritoneal bladder flap in rarp patients on lymphoceles

Conditions: Lymphocele After Surgical Procedure

Summary: a two-armed prospective randomised, controlled, single-centre trial on 1080 patients with prostate cancer who underwent robot-assisted radical prostatectomy with bilateral pelvic lymph node dissection was carried out. patients in the intervention arm received fixation of the peritoneal flap of the bladder to the plexus santorini at the end of surgery (michl-technique, mt); in the control group, surgery was performed without this modification. the primary endpoint was the rate of lymphoceles requiring intervention.


Eligibility criteria:
inclusion criteria: * declaration of consent signed * minimum age 18 years * localised prostate carcinoma * planned dvrp with bilateral lymphadenectomy exclusion criteria: * patient's lack of capacity to consent * orp * no planned plnd * metastatic prostate cancer * asa status \>3

Keywords: prostate cancer radical prostatectomy pelvic lymph node dissection lymphocele complication
an observational pilot study of lumosity computerized cognitive training in subjects with multiple sclerosis

Conditions: Multiple Sclerosis (MS)

Summary: in collaboration with the mercy ms achievement center, lumos labs is proposing an open-label, 12-month pilot study of computerized cognitive training as part of the cognitive wellness program in order to evaluate (1) the user experience of lumosity in individuals with ms, and (2) the efficacy of lumosity for improving cognitive outcomes in individuals with ms.

approximately 50 current members of the mercy ms achievement center will be provided with 12-month premium access lumosity accounts. study participants must be ≥18 years of age, and currently members of the achievement center participating in the cognitive wellness program. those who consent will be provided with an account activation code and instructed on how to sign up for lumosity. upon creating an account, users would be asked to complete a short demographic survey (information about you, which includes age, sex, race/ethnicity, education, occupation) and two additional short surveys: a computer experience questionnaire and a perceptions of brain training questionnaire. in addition, participants will be assessed with the montreal cognitive assessment (moca), and be directed to take the brain performance test (on a laptop or desktop computer) within the first 7 days of creating their account. if not conducted within the previous 3 months, participants would also be required to have the following assessments at baseline (i.e., within the first 7 days): multiple sclerosis neuropsychological questionnaire (msnq), multiple sclerosis impact scale-29 (msis-29), and beck depression inventory (bdi). after one week of using lumosity, and then every other month for 12 months, participants would be asked to complete a short questionnaire about their experience with lumosity. every 3 months, participants would repeat the bpt, msnq, and bdi; and every 6 months, they would repeat the msis. finally, at the end of the study, the end of the study they would also repeat the moca.

Eligibility criteria:
inclusion criteria: participants must meet the following criteria: 1. signed informed consent 2. 18 years of age or older, 3. english-speaking, 4. current participants in the ms achievement center cognitive wellness program 5. sufficient physical capacity to use a computer keyboard and mouse 6. willing and able to use lumosity at least 3 times per week exclusion criteria: participants who meet any of the following criteria will be excluded from participation: 1. under 18 years of age 2. are taking medication that may impede cognitive functioning 3. have other conditions or problems that may preclude regular computer usage
effects of heart rate oscillations during meditation on plasma biomarkers of alzheimer's disease

Conditions: Alzheimer Disease

Summary: in the current study, we will examine how two types of concentration meditation practices affect plasma biomarkers of alzheimer's disease (ad). we will also examine the effects of the two types of meditation practices on emotional well-being and episodic memory. healthy adults aged 18-35 who meet all eligibility criteria will be invited to this study. participants will be asked to engage in one week of daily meditation practice or no-intervention control task at home. they will also be asked to visit the lab twice, once before and once after the intervention, to provide blood samples to assess plasma biomarkers of ad and to complete emotion questionnaires and a memory test.


Eligibility criteria:
inclusion criteria: * fluent in english * aged between 18-35 years old * agree to provide blood samples * healthy adults who weigh at least 110 pounds * agree to devote 40 minutes daily to this study for a week exclusion criteria: * have a disorder that would affect heart rhythm or function (e.g., abnormal cardiac rhythm, dyspnea, heart disease including coronary artery disease, angina and arrhythmia) * regularly practicing any relaxation, meditation or yoga that involve breathing focused practices lasting for more than an hour each week
moderate intensity aerobic training in sub-acute and chronic stroke patients - the influence on brain derived neurotrophic factor (bdnf) and upper-limb rehabilitation. a protocol for a randomized control trial and health economic evaluation

Conditions: Stroke

Summary: the aim of this study is to evaluate the influence on three different training modalities on the blood concentration levels of a growth factor called brain derived neurotrophic factor (bdnf) and on the recovery of arm function following in sub-acute and chronic stroke survivors. the training modalities are 1. moderate intensity aerobic training on a bike ergonometer followed by robotic or sensor-based upper-limb training, 2. non-aerobic circuit training followed by robotic or sensor-based upper-limb training 3. circuit training alone.

background and rationale:brain-derived neurotrophic factor (bdnf) belongs to a group of neurotrophins which influence neuroplasticity by increasing long-term potentiation and axonal and dendritic growth. levels of serum bdnf are increased following moderate intensity aerobic exercise (mae) in animal and healthy subjects. the influence of mae on bdnf following stroke and the resultant efficacy of motor training in this environment remains unclear. objective(s):to investigate the influence of mae on acute and chronic levels of serum bdnf in sub-acute and chronic stroke patients, the efficacy of robotic upper limb or sensor based motor task training in this environment and consequent effect on functional arm recovery compared to the same upper limb training following non-aerobic training circuit training, or non-aerobic circuit training alone to evaluate the cost-effectiveness of the interventions. study interventions: group 1: moderate intensity ae 40 minutes, 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb training. group2: non-aerobic gait and balance circuit training 40 mins 3 times weekly followed after 20 minutes break by 40 minutes robotic or sensor-based upper-limb training, group 3: 40 minutes non-aerobic gait and balance circuit training.in total 45 participants will be enrolled - 15 in each group.study duration:3 monthly intervention period per intervention group, with a 3 month and 6 month follow-up. .

Eligibility criteria:
inclusion criteria: * hemiplegic stroke ischemic or intracerebral hemorrhagic \> 3 months post- stroke * active shoulder abduction, wrist and finger extension 10 degrees from a flexed position exclusion criteria: * contraindications to maximal exercise testing according to the american college of sports medicine guidelines * severe perceptual problems * concurrent neurological diagnoses e.g. parkinsons disease * comorbidities which may interfere with exercise participation * significant cognitive impairment \< 24 on the montreal cognitive assessment scale
pulmonary vascular disease and cardiac performance in extreme preterm infants

Conditions: Prematurity; Extreme

Summary: pulmonary vascular disease and cardiac performance in extreme preterm infants: a prospective cross-sectional study

the principal investigator hypothesize that premature newborns have disturbed cardiac performance and increased pulmonary pressures during neonatal life and at different pediatric ages. the principal investigator also hypothesize that premature newborns with poor cardiac performance and/or pulmonary hypertension have higher morbidities and poorer neuro-developmental outcomes. the principal investigator also hypothesize that premature newborns with poor cardiac performance and/or pulmonary hypertension have higher morbidities and poorer neuro-developmental outcomes and that novel echocardiography techniques will detect anomalies not uncovered by conventional imaging, and that early echocardiography may identify those with later pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * infants born at \<29 weeks' gestational age admitted to the nicu * all infants born at \<29 weeks' gestational age followed at mch clinic after an admission in the nicu for prematurity \<29 weeks exclusion criteria: * congenital heart disease (except an atrial (asd) or ventricular septal defect (vsd), or a patent ductus arteriosus (pda)) * congenital severe lung or airway malformation (choanal atresia, trachea-esophageal fistula or congenital pulmonary airway malformation) * genetic disorder (trisomy 21).
expanded access to elezanumab

Conditions: Acute Spinal Cord Injury (SCI); Acute Ischemic Stroke

Summary: this is an expanded access program (eap) for eligible participants. this program is designed to provide access to elezanumab prior to approval by the local regulatory agency. availability will depend on territory eligibility. a medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.


Eligibility criteria:
inclusion criteria: - the participant must not be eligible for an elezanumab clinical trial.

Keywords: expanded access pre-approval access compassionate use special access program named patient basis special access scheme
power myocardial fatigue study: a biomechanical assessment of contractility of human myocardium

Conditions: Heart Failure; Fatigue; Muscle, Heart; Myocardial Dysfunction; Exhaustion; Heart

Summary: to gain a comprehensive understanding of the biomechanical behaviour of human heart to explore the concept of myocardial fatigue in response to a temporal range of preload, afterload and drug-induced inotropy using in-vitro contractile assays.

a continuum of pathological states from fatigue, injury to damage of the myocardium has been proposed which complements the continuous spectrum of hf and reconciles the seemingly disparate plethora of mechanisms behind the pathophysiology of hf. unlike skeletal muscle where mechanical stress can be readily removed upon fatigue, an impaired left ventricle continues to receive preload from the right ventricle and cannot rest, maintaining cardiac output only at the expense of increasing filling pressures (as in hf with preserved ejection fraction). if concurrently faced with high afterload from vascular stiffness, ventricular-arterial decoupling occurs, driving mechanical inefficiency and diminishing cardiac output (as in hf with reduced ejection fraction). chances of recovery is linked to the degree of fatigue, cardiomyocyte loss and replacement with non-contractile fibrosis. assuming that the myocardium is in a state of chronic fatigue before reaching advanced stages of fibrosis, cases such as aortic stenosis or hypertensive heart disease may potentially be reversible if the pathological load is promptly removed. this study will be re-synthesizing existing knowledge of the biomechanical behaviour of healthy and diseased cardiac myocytes and muscle in a new light of the theoretical constructs of myocardial fatigue, aligned with the existing energy-starvation theory. it will be a proof-of-concept study. just as frank-starling's relationship between preload and cardiac output emerged from pre-clinical studies on muscle behaviour with subsequently major clinical implications, this study represents a necessary stepping stone to adding a new layer of insight into the pathophysiology of heart failure (hf).

Eligibility criteria:
inclusion criteria: * all adult patients between 18 to 85-years old undergoing open-heart surgery who can undergo the consent process for the study * healthy donor hearts that are deemed non-transplantable and consent received from a legal representative exclusion criteria: this criterion is kept to a minimum since the availability of human myocardial samples is finite and dependent on the limited number of patients undergoing cardiac surgery annually within the local hospital. * patients who do not have the mental capacity to undergo the consent process * for the safety of researchers, patients with evidence of ongoing blood-borne infections such as hiv, or a recent positive test for covid-19 (within 10 days of last pcr test).

Keywords: myocardial fatigue preload afterload cardiac work-loop cardiomyocytes biomechanical model
development of a risk prediction screening tool for opioid-prescription injury (stop injury) in older adults initiated on opioids from the emergency department

Conditions: Opioid Use

Summary: the long-term goal of this project is to promote responsible opioid prescribing, immediately improving patient safety and ultimately decreasing healthcare costs by reducing older adult morbidity and mortality due to opioid-related injury. the objective of this pilot project is to gather data to inform the development of the stop injury tool and evaluate additional predictive factors and important outcomes relevant to prescription opioids.

the experience from this project will lay the groundwork on prospective validation of stop injury in a large appropriately powered study. aim 1 will provide data that will help narrow inclusion of candidate variables in the stop injury tool to include those that are most feasible to collect and most predictive. aim 2 will help inform the possible inclusion of genetic factors into a predictive model. finally, aim 3 will help identify quality of life outcomes that should be considered when assessing opioid medication adverse events. aim 1. evaluate the association between prescription opioid adverse events in older adults and candidate risk prediction variables proposed for stop injury prediction score the study team will conduct a pilot prospective observational study of 200 patients 50 years or older who are initiated on opioids from the emergency department (ed). the investigators will analyze the association between candidate risk factors and opioid adverse events (falls and od). aim 2. evaluate the association between prescription opioid adverse events and genetic factors. in the cohort from aim 1, the study team will test subjects for 12 genetic single nucleotide polymorphisms related to opioid metabolism, transport, and effect. aim 3. measure the impact of opioid medications on quality of life measures in older adults the investigators will implement a series of quality of life measures on a subset of patients as a pilot study to determine which measures capture the impact prescription opioids have on older adults' quality of life

Eligibility criteria:
inclusion criteria: * presenting to uf jax ed with pain or a pain-related complaint (i.e., fracture, burn, etc.) * patient has not used opioids 15 days or more within the last 30 days * patient does not have opioid medications at home * discharge to home with an opioid prescription exclusion criteria: * bed-bound or uses wheelchair * living in skilled nursing facility or assisted living facility * non-english speaking * unable to provide consent * incarcerated * lack of reliable telephone access * use of opioids on most days for \>3 months

Keywords: older adults quality of life adverse events
the factors associated with the recurrence in patients with cushing disease

Conditions: Cushing Disease

Summary: cushing syndrome refers the manifestations induced by chronic glucocorticoid excess and may arise from various causes. iatrogenic cushing syndrome accounts for most patients, when they are given exogenous glucocorticoid treatment. in contrast, spontaneous cushing syndrome results from endogenous glucocorticoid over-secretion. although cushing disease is rare, it is the most common cause of spontaneous cushing syndrome. the patient with cushing disease has a pituitary corticotroph adenoma, which overproduces adrenocorticotropic hormone (acth). acth then stimulates adrenal gland to over-secret glucocorticoid. patients with untreated cushing disease were shown to have poor prognosis, estimated a 5-year survival rate of 50%. the first line treatment is tumor resection. other managements include radiotherapy, medication and bilateral adrenalectomy. the initial remission rate is high (66-90%). however, some patients encounter with disease recurrence during follow-up. the aim of this study is to clarify the factors associated with the recurrence after treatment. in this study, we will review the patients with cushing disease thoroughly and analyze associated predisposing factors. these risk factors can remind the clinical physician to early detect the recurrent disease in these patients, and further prevent morbidity and mortality in their later lives.


Eligibility criteria:
inclusion criteria: * clinical diagnosed cushing's disease exclusion criteria: * already received treatment in other hospital * ectopic cushing's syndrome
differences between women with covid-19 and long covid

Conditions: COVID-19

Summary: the coronavirus disease of 2019 (covid-19) has infected more than 630 million people and resulted in more than 6.5 million deaths worldwide. among the possible sequelae of the virus, a disorder called long covid has shown to affect about 10% of those infected, mostly adult women, without comorbidities. long covid corresponds to a multisystemic syndrome following the acute period of the disease, in which the person maintains persistent symptoms such as fatigue, dyspnea, cough, memory loss, muscle and joint pain, among others. now that time has passed, it is necessary to verify why there are women who present symptoms of long covid and others do not.


Eligibility criteria:
inclusion criteria: * women between 18 and 65 years * that they have passed covid-19 at least once. * whether or not they have symptoms secondary to covid-19. exclusion criteria: * they do not want to sign the informed consent.

Keywords: covid-19 long covid women